StockMarketTrends
-
CrowdStrike Isn’t Failing — Investors Just Overpaid for Perfection
CrowdStrike was supposed to be the untouchable king of cybersecurity. So why is CRWD wobbling in 2026? Here’s the uncomfortable truth: this stock isn’t just about cybersecurity anymore. It’s about expectations. And those expectations got out of hand. The Setup: Growth King Meets Reality CrowdStrike built a monster business. Recurring revenue. Fat gross margins. Expanding…
-
Apple Isn’t Headed to $300 — Until It Earns It
Is Apple about to rip to $300 — or roll over to $230? That’s the question hanging over AAPL right now. After a monster Q1 FY2026 (revenue up 16% YoY, EPS up 19%, iPhone revenue up 23%), the stock is sitting in that uncomfortable middle zone around $252–$260. Not broken. Not breaking out. Just… coiling.…
-
Marvell Is a Real Bet on AI — Bausch Is a Debt Bet in Disguise
Jim Cramer says buy Marvell and Bausch. The real question isn’t whether he’s excited — it’s whether the numbers and the charts back him up. Let’s start with Marvell (MRVL), because this one actually has receipts. Marvell just posted fiscal 2026 revenue of $8.2B, up 42% year over year. Q4 alone came in at $2.2B,…
-
Follow the Money, Not the Turnaround: Why I’m With Cramer on Marvell
Should you fade Jim Cramer… or follow him? That’s the eternal Lightning Round question. And this week, with Marvell (MRVL) getting Cramer’s stamp of approval while Bausch Health (BHC) quietly grinds through another turnaround quarter, traders have a real fork in the road. Here’s the call: Follow Cramer on Marvell. Fade the complacency on Bausch.…
You must be logged in to post a comment.